RIVA AZITHROMYCIN TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
17-03-2015
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE)
Fáanlegur frá:
LABORATOIRE RIVA INC.
ATC númer:
J01FA10
INN (Alþjóðlegt nafn):
AZITHROMYCIN
Skammtar:
600MG
Lyfjaform:
TABLET
Samsetning:
AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE) 600MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
6
Gerð lyfseðils:
Prescription
Lækningarsvæði:
OTHER MACROLIDES
Vörulýsing:
Active ingredient group (AIG) number: 0126072005; AHFS:
Leyfisstaða:
CANCELLED POST MARKET
Leyfisdagur:
2013-07-31
Vara einkenni
_ _
_RIVA-Azithromycin _
_ _
_Page 1 of 56 _
PRODUCT MONOGRAPH
Pr
RIVA-AZITHROMYCIN
Azithromycin Tablets USP
250 mg and 600 mg
Antibiotic
LABORATOIRE RIVA INC.
660 Industriel blvd.
Blainville, Quebec, Canada.
J7C 3V4
www.labriva.com
Control No. 182319
Date of Revision:
March 17, 2015
_ _
_RIVA-Azithromycin _
_ _
_Page 2 of 56 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
...........................................................................................................
9
DRUG INTERACTIONS
..........................................................................................................
15
DOSAGE AND ADMINISTRATION
......................................................................................
19
OVERDOSAGE
........................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
21
STORAGE AND STABILITY
.................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
.................................................................................
25
CLINICAL TRIALS
...................................................
Lestu allt skjalið
